Safety, Immunogenicity, and Hemostatic Efficacy of Nonacog Gamma in Patients With Severe or Moderately Severe Hemophilia B: A Continuation Study

This phase 3, prospective, open-label, multicenter, continuation study (NCT01286779) investigated the use of a recombinant factor IX (FIX), nonacog gamma (BAX 326, RIXUBIS ® ) in patients with severe or moderately severe hemophilia B. The study population included 85 patients transitioning from a ph...

Descripció completa

Dades bibliogràfiques

Autors principals:	Jerzy Windyga MD, PhD, Oleksandra Stasyshyn MD, PhD, Toshko Lissitchkov MD, PhD, Vasily Mamonov MD, PhD, Margit Serban MD, PhD, Luminita Rusen MD, PhD, Bettina Ploder MSc, Srilatha Tangada PhD
Format:	Artigo
Idioma:	Inglês
Publicat:	SAGE Publishing 2020-08-01
Col·lecció:	Clinical and Applied Thrombosis/Hemostasis
Accés en línia:	https://doi.org/10.1177/1076029620950836
Etiquetes:	Afegir etiqueta Sense etiquetes, Sigues el primer a etiquetar aquest registre!